Please assess the completion status of the following clinical trial:

Trial Title: Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients infected with VIH-1, documented with a positive HIV-1 antibody test and/or positive PCR, confirmed for HIV-1 RNA.~* Patients treated with a HAART that should contain AZT+3TC+ABC (Trizivir®)~* Patients with an indetectable viral load, which will be defined \<40 copies/mL within the last six months.~* Patients with a lipoatrophy clinical evidence (which will be defined as moderate or severe, according to the Lipodystrophy Severity Grading Scale).~* Men or women aged ≥ 18.~* For women of childbearing potential, negative urine pregnancy test during the Screening visit.~* Patients that have signed and dated the Informed consent Form prior to any Study-specific procedure.~Exclusion Criteria:~* Patients with evidence of protease inhibitors failure, and/or documented evidence of protease gene resistance mutation. This evidence could be prior or during the inclusion period in the Study.~* Patients who, for any reason could not be treated with LPV/r.~* Cachexia, defined as an Body Mass Index \<17 Kg/m2.~* Pregnant or breastfeeding women, or women of childbearing potential who do not use the appropriate contraceptive method, according to the Investigator judgment.~* Clinically relevant disease or condition, according to the Investigator judgment, three months prior to the patient inclusion in the Study.~* Patients taking the following concomitant medication that could affect the adipocyte function or morphology, such as: insulin, steroids, anabolic steroid, anti-inflammatory medication for more than three months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Kaletra, all patients (Type: EXPERIMENTAL): Patients will change actual treament for monotherapy LPV/r. They only will take Kaletra 2/day

Based on this trial design, predict the completion outcome and termination type (if applicable).